Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finafloxacin - MerLion Pharmaceuticals

Next Previous
Drug Profile

Finafloxacin - MerLion Pharmaceuticals

Alternative Names: AL-60371; BY-377; EXE 844; EXE 844b; Finafloxacin hydrochloride; Gastrochinolon; Gastroquinolone; Xtoro

Latest Information Update: 16 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Alcon; MerLion Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluoroquinolones; Small molecules; Urinary anti-infective agents
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Otitis externa
  • Phase II Helicobacter infections; Pyelonephritis; Urinary tract infections
  • Preclinical Melioidosis
  • No development reported Bacterial infections
  • Discontinued Otitis media; Respiratory tract infections

Most Recent Events

  • 11 Dec 2024 Finafloxacin licensed to Fonseca Biosciences in USA
  • 11 Dec 2024 Fonseca Biosciences announces intention to launch Finafloxacin for Otitis externa in mid-2025
  • 12 Sep 2024 Discontinued - Phase-I for Otitis media (In children, In infants) in USA (Otic) prior to September 2024 (MerLion Pharmaceuticals pipeline, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top